China Biologic Products Holdings, Inc.
CBPO
CBPO was delisted on the 20th of April, 2021.
131 hedge funds and large institutions have $2.15B invested in China Biologic Products Holdings, Inc. in 2016 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 48 increasing their positions, 39 reducing their positions, and 13 closing their positions.
154% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 13
23% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 39
15% more funds holding
Funds holding: 114 → 131 (+17)
19% less capital invested
Capital invested by funds: $2.67B → $2.15B (-$516M)
20% less call options, than puts
Call options by funds: $15M | Put options by funds: $18.8M
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$211M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$121M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$93.3M |
| 4 |
HIM
Hermes Investment Management
London Uk,
United Kingdom
|
+$25M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$20.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Warburg Pincus
New York
|
-$499M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
-$29.6M |
| 3 |
ACM
Ariose Capital Management
Central, Hong Kong,
Hong Kong
|
-$18.6M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$17.7M |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$12.7M |
CBPO Hedge Fund Activity: Q1 2016 in Review
131 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q1 2016, worth a combined $2.15B — down 19% from $2.67B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new CBPO positions and 13 closed out — a net gain of 20 holders — while 48 added to existing stakes and 39 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $211M. The largest seller was Warburg Pincus, cutting an estimated $499M.
- 131 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q1 2016, up from 114 in Q4 2015.
- Funds reported $2.15B of China Biologic Products Holdings, Inc. stock for Q1 2016, down 19% quarter-over-quarter.
- 33 funds opened new China Biologic Products Holdings, Inc. positions in Q1 2016 and 13 closed out, a net change of +20 holders.
- The largest China Biologic Products Holdings, Inc. buyer in Q1 2016 was Capital Research Global Investors, an estimated $211M added.
- The largest China Biologic Products Holdings, Inc. seller in Q1 2016 was Warburg Pincus, an estimated $499M sold.
Based on aggregated 13F filings for Q1 2016.